Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

F, such as TB-403, can selectively inhibit tumor growth by blocking its blood supply without affecting normal tissues. TB-403 is now in Phase I development.

- ThromboGenics may enter into partnerships or license agreements to commercialize its products and this preferably after Phase II.

Financial Summary

- In 2007, revenue amounted to EUR1.5m, mainly coming from out-licensing. Operating expenses were EUR20.0m in 2007, the majority of which were due to R&D expenses related to our increasing number of clinical development programs. The net loss for the year was EUR16.0m.

- As of 31 December 2007, ThromboGenics had EUR46.1m in cash and cash equivalents. This compared to EUR32.04m on 31 December, 2006, and results from the fundraising that the Company completed in May 2007.

- The Group streamlined its organization with the absorption of the fully owned subsidiary Thromb-X.

Prof Desire Collen, CEO of ThromboGenics, commenting on today's announcement, said: "I am very pleased with what we have achieved during the course of 2007, particularly the successful fund raising we completed in May, which broadened our shareholder base. The additional funds raised will allow us to advance our exciting clinical development portfolio, which is progressing as planned. I am also very happy with the encouraging results that we have obtained with microplasmin in clinical trials targeting "back of the eye" diseases. These results further strengthen our belief that this product will be of great value to the ophthalmic community. In addition, we have made good progress with our earlier programs, including anti-PlGF (TB-403), where our Cell paper generated significant interest in this exciting new approach for cancer therapy, and which progressed to Phase I."

The full financial results statement can be found at http://www.thrombogenics.com

About ThromboGenics

ThromboGenics
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Pipette.com has ... to their comprehensive portfolio of Eppendorf products. , ... to purchase a Centrifuge 5424/5424 R and receive the ... either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... N.Y., April 6, 2011 Health Care Compliance ... Health System of Detroit, MI., has selected the ... with the conflict of interest disclosure process. COI-SMART ... than 20,000 employees. (Logo: http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO) ...
... Fla., April 5, 2011 Embryo Donation International ... donation facilities in the United States, officially opened today ... the globe desiring to build a family.     ... dedicated mission is to reduce the number of ...
... BALTIMORE, April 5, 2011 Champions Oncology, Inc. (OTC: CSBR) ... it has completed the private placement of 12.5 million shares ... share, resulting in gross proceeds to the company of $9.4 ... used to invest in: Sales resources dedicated ...
Cached Biology Technology:Conflict of Interest Management System Selected by Henry Ford Health System 2A New Company Is Born - Embryo Donation International 2Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing 2Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing 3
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a new ... this $50 million capital project is part of a larger ... The medical education building will be located in ... to 525@vine in Wake Forest Innovation Quarter. Construction will begin ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... 26, 2011 The world,s largest scientific society picked the perfect ... the American Chemical Society (ACS) Office of Public Affairs invites your ... venue for the theme The Chemistry of Air, Space and ... in and near Denver ranging from hot air balloon rides, ...
... Scientists seeking to improve cancer treatments have created a ... genes by finding the equivalent of an expressway into a ... lipid-based structure containing a piece of RNA. Lipids are fatty ... The RNA segment encased in the carrier sets off ...
... Metastasisthe spread of cancer from the place where it ... most common reason that cancer treatments fail. To metastasize, ... membrane projections that act like feet, helping them "walk" ... To determine how cells control invadopodia formation, scientists at ...
Cached Biology News:News media registration for American Chemical Society National Meeting Denver, Aug. 28-Sept. 1, 2011 2Scientists design nano-sized drug transporter to fight disease 2Scientists design nano-sized drug transporter to fight disease 3High-throughput screen finds compounds that regulate cancer cell invasion 2High-throughput screen finds compounds that regulate cancer cell invasion 3